MOLECULIN BIOTECH INC (MBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.71+5.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MBRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue pivotal Phase 2/3 MIRACLE trial with enrollment, interim data readouts, dose selection, and Part B initiation planned through 2027.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a July 2026 update. Management reported positive interim MIRACLE trial results with complete remission rates three times higher than control and enrollment progressing from 45 subjects in 2026-Q1 to over 80 by 2026-Q2, targeting 90 subjects by September 2026. The unblinded data readout is expected between December 2026 and February 2027, with Part B initiation planned for first half 2027. The trajectory is delivering consistent clinical progress as outlined.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Positive interim MIRACLE data showed complete remission rates three times higher than control; enrollment on track for 90-patient milestone in September 2026.”
“Enrollment surpassed first interim analysis threshold; 45 subject blinded data supports Annamycin's potential in relapsed/refractory AML.”
Maintain financial discipline to support operations with current cash and recent financing expected to fund through early 2027.
Management stated this priority in 3 quarters including 2026-Q1 and 2026-Q2. Cash and cash equivalents declined from $10.3 million in 2026-Q1 to $7.3 million in 2026-Q2, with $9.3 million raised post-quarter. Management expects these resources to fund operations into early 2027. The trajectory shows active cash management with financing to sustain operations, consistent with management's statements.
“Cash on hand and cash equivalents as of June 30, 2026, together with $9.3 million in financing proceeds raised subsequent to the quarter, expected to support planned operations into the first quarter…”
“Management believes current cash resources, together with recent financing proceeds, will support planned operations into the third quarter of 2026.”
“Cash and cash equivalents were $8.9 million as of December 31, 2025.”
Raise capital via public offerings and warrant exercises to support clinical development and operations.
Capital raising was stated in 2 quarters: 2026-Q1 and 2026-Q2. The company completed financing transactions raising approximately $8.3 million in 2026-Q1 and announced a public offering of 12,376,667 shares or pre-funded warrants in 2026-Q2. These activities align with management's stated capital allocation priorities and support ongoing operations and clinical development.
“Entered into a placement agency agreement for public offering of 12,376,667 shares or pre-funded warrants.”
“Completed financing transactions during the first quarter of 2026 resulting in approximately $8.3 million in gross proceeds.”
Broaden clinical trial sites in US and Europe and strengthen IP coverage across four continents for Annamycin.
Stated in 2 quarters: 2026-Q1 and 2026-Q2. Management reported ongoing expansion of clinical trial operations in the US and Europe and strengthened intellectual property strategy covering four continents. Enrollment progressed from 45 subjects in 2026-Q1 to over 80 in 2026-Q2, supporting this priority. The trajectory shows delivering progress in trial expansion and IP strategy.
“Strong investigator engagement and enrollment progress in MIRACLE trial across multiple countries.”
“Continued expansion of clinical trial operations across the United States and Europe to support accelerated enrollment.”
Advance development of WP1066 and WP1122 for brain tumors, pancreatic cancer, and pathogenic viruses alongside Annamycin.
This priority was stated in 3 quarters including 2026-Q1 and 2026-Q2. Management continues to support development of WP1066 and WP1122 for cancers and viral diseases alongside Annamycin. While no specific financial or clinical milestones were reported, the recurring statements indicate ongoing commitment with limited specific delivery data.
“Moleculin continues to support development activities for WP1066 and pipeline candidates including WP1122.”
“Developing WP1066 targeting brain tumors, pancreatic and other cancers, and WP1122 for pathogenic viruses.”
Over the trailing year it converted 0.65x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
19 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.